Invest in MJ Blog

Kelowna, BC / August 24, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is very pleased to announce potential industry-changing achievements in enhanced gastro-intestinal absorption of cannabidiol (CBD) utilizing Lexaria’s patent pending technology. The recent thirdparty testing was conducted in two phases of in vitro tests beginning in June and completed in August, 2015.

The independent laboratory results have delivered average CBD permeability of 499% of baseline permeability, compared to CBD permeability without Lexaria’s technology. These results exceed Company expectations.

This was assessed in a strictly controlled, in vitro experiment using a human intestinal tissue model. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patent-pending formulation and process enhancements. Lexaria believes that its in vitro findings provide compelling evidence of the intestinal absorption enhancing capabilities of its technology, based on which it is exploring opportunities to progress to more advanced, follow-on bioavailability testing in animals.

Boulder, Colorado-based Tradiv is raising a $1 million round as it gears up to launch its B2B marketplace for cannabis cultivators, marijuana infused product companies, and dispensaries.

That’s right: The B2B pot ecosystem is unfolding right before our eyes.

Backed by Cannabis accelerator CanopyBoulder and accelerator partner Micah Tapman, Tradiv revealed the raise in a public filing with the U.S. Securities and Exchange Commission. The weed startup has so far raised $650,000, according to the filing — at least $20,000 of which likely came from CanopyBoulder, in exchange for a whopping 9.5 percent equity stake. The filing also lists Emily Paxhia, partner of Cannabis-only fund Poseidon Asset Management; and former Microsoft Surface manager, Nick Hofmeister.

See Original Blog Post

August 5, 2015 

Pennsylvania drugmaker Zynerba Pharmaceuticals ($ZYNE) is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.

The company priced 3 million shares at $14 each, the middle of its range, and set aside another 450,000 shares for its underwriters to line up for as much as $51.8 million in total.

With the proceeds, Zynerba will press forward with a pair of early-stage transdermal patches that mete out cannabinoid chemicals to treat a host of CNS ailments. ZYN002, slated to enter clinical trials in the second half, has shown promise in refractory epilepsy, Fragile X syndrome and osteoarthritis pain, the company said. And ZYN001, in line for Phase I next year, targets fibromyalgia and peripheral neuropathic pain.

The promise of cannabis-derived pharmaceuticals has drawn a slew of companies to the field over the past few years, including GW Pharmaceuticals ($GWPH) and Insys Therapeutics ($INSY). But unlike its further-along competitors, Zynerba's treatments are synthetically manufactured and don't require growing and maintaining cannabis plants, which the company bills as a practical and financial advantage. Furthermore, Zynerba's transdermal therapies get their active ingredients straight into the circulatory system, avoiding the bioavailability issues that can plague oral treatments that must first navigate the stomach and liver.

Zynerba is led by CEO Armando Anido, appointed in 2014 after stints at the helm of Auxilium Pharmaceuticals, acquired by Endo Pharmaceutical ($ENDP) for about $2.6 billion, and NuPathe, which went to Teva ($TEVA) for $144 million last year.

Meanwhile, biotech's ongoing IPO boom has continued unabated into the second half of 2015, marked by a record debut for Patrick Soon-Shiong's NantKwest ($NK). And the queue of drug developers angling to go public remains full, as Zynerba joins a group including gene therapy outfit Gensight Biologics and food allergy biotech Aimmune Therapeutics.

The original post can be seen here.

Transaction Unites Canada’s Two Strongest Cannabis Brands, and Establishes World’s Largest Publicly-Traded Cannabis Producer

June 24, 2015 – Toronto and Smiths Falls, Canada – Tweed Marijuana Inc. (“TMI” or “Tweed”) (TSXV: TWD), operator of licensed cannabis producers Tweed Inc. and Tweed Farms Inc., and Bedrocan Cannabis Corp. (“Bedrocan Canada”) (TSXV: BED) are pleased to announce that they have entered into a definitive arrangement agreement, pursuant to which TMI will acquire all of the issued and outstanding securities of Bedrocan Canada. TMI will be renamed at its annual meeting of shareholders to reflect its evolution as a multi-brand holding company. This acquisition marks the beginning of the structured evolution of the Canadian cannabis sector, and it is intended that TMI’s portfolio of technologies, brands and geographies will continue to expand.

BOULDER, Colorado and SAN DIEGO, California—June 16, 2015—Shift Cannabis Company and Innovative Solutions today announced a dynamic alliance that teams the market-leading strengths of each company to transform the medical cannabis industry. Through the use of the Puradigm cutting edge technology, used to manage and control microbial, mold, and pathogen growth during indoor cultivation, these two companies are tackling head-on one of the most prominent and pertinent issues facing the commercial cannabis industry today.

The alliance aims to redefine the way medical cannabis growers produce product using the advanced Puradigm technology to purify the air and surfaces in the grow environment. Working together Shift Cannabis Co. and Innovative Solutions will be able to address key cannabis industry cultivating challenges including:

• Controlling microbial and pathogens throughout the production facility
• Purifying air and surfaces in grow rooms for clean flower development
• Managing the dry and cure process by attacking gray mold and botrytis
• Providing a clean process for packaging and storage of clean product

Shift Cannabis Co. is involved in all core markets of the cannabis industry from seed to sale providing professional business services to retailers and producers alike. With over a decade of commercial, regulated cannabis cultivation expertise, and over fifteen years of combined experience in cannabis organizational management including Lean and Six-Sigma Processing, their leadership team only utilizes products that work. When asked about his corporate culture Travis Howard, Founder and General Manager of Shift, had this to say, “As a former attorney I was used to being able to test theories against long-standing case law so I made sure our team had test gardens, places where they could break and fix, infect and clean, really put inventions to work under real-life demanding circumstances. If we haven’t used it, effectively, we don’t consult it. Period.”